Patent application number | Description | Published |
20090023596 | In Vitro Model Of Latent Mycobacterial Infection - A method of inducing latency in | 01-22-2009 |
20100041736 | Isolated MCPIP and Methods of Use - A monocyte chemoattractant protein (MCP-1)-inducible protein, MCPIP, its polynucleotide and amino acid sequences from mouse and human, and methods for its use are disclosed. | 02-18-2010 |
20110033914 | In Vitro Model of Latent Mycobacterial Infection - A method of inducing latency in | 02-10-2011 |
20130195882 | MCPIP PROTECTION AGAINST OSTEOCLAST PRODUCTION - Disclosed herein are methods of treating a patient at risk of developing an inflammatory joint disease. In exemplary embodiments, the method involves inhibiting MCPIP levels in a patient in need, wherein said patient in need is exhibiting pre-arthritic or pre-osteoporotic symptoms. | 08-01-2013 |
20140302044 | MCPIP PROTECTION AGAINST OSTEOCLAST PRODUCTION - Disclosed herein are methods of treating a patient at risk of developing an inflammatory joint disease. In exemplary embodiments, the method involves inhibiting MCPIP levels in a patient in need, wherein said patient in need is exhibiting pre-arthritic or pre-osteoporotic symptoms. | 10-09-2014 |
Patent application number | Description | Published |
20100008903 | TARGETING OF LONG CHAIN TRIACYLGLYCEROL HYDROLASE GENE FOR TUBERCULOSIS TREATMENT - Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the implementation or manipulation of triacylglycerol hydrolase like polypeptides or polynucleotides encoding the same. The methods are useful in identifying agents active against TB infection. | 01-14-2010 |
20100021453 | TARGETING OF TRIACYLCLYCEROL SYNTHASE GENE FOR TUBERCULOSIS TREATMENT - Disclosed herein are novel methods for screening for compounds useful in treating or preventing tuberculosis. In exemplary embodiments, screening methods are based on the implementation or manipulation of triacylglycerol synthase like polypeptides or polynucleotides encoding the same. The methods are useful in identifying agents active against TB infection. | 01-28-2010 |
20110002981 | MCPIP Protection Against Cardiac Dysfunction - Disclosed herein are methods and compositions of treating a patient at risk of experiencing sepsis induced cardiac dysfunction. In exemplary examples, the method involves elevating MCPIP levels in a patient in need. Elevating MCPIP levels may involve direct administration (e.g. delivery of protein) or indirect administration (e.g. delivery vehicle capable of increasing expression of MCPIP). | 01-06-2011 |
20110033915 | In Vitro Model of Latent Mycobacterial Infection - A method of inducing latency in | 02-10-2011 |
20130040829 | IN VITRO MODEL OF LATENT MYCOBACTERIAL INFECTION - A method of inducing latency in | 02-14-2013 |
20130295076 | MCPIP AS WOUND THERAPY - Disclosed herein are methods and compositions of treating a subject suffering from a wound. In exemplary examples, the method involves elevating MCPIP levels in a subject in need. Elevating MCPIP levels may involve direct administration (e.g. delivery of protein) or indirect administration (e.g. delivery vehicle capable of increasing expression of MCPIP). | 11-07-2013 |